3.0
Viatris Inc. is a corporation listed on Nasdaq under the ticker VTRS, operating in the healthcare sector and the global pharmaceutical subsector. The corporate structure was formed through the strategic combination of established international operations following the merger between Mylan N.V. and Upjohn, a division of Pfizer. The resulting entity was designed to expand access to medicines and strengthen broad therapeutic portfolios across multiple regions.
The portfolio includes generic medicines, branded drugs, biosimilars, specialty treatments, and products for chronic conditions. Offerings span cardiovascular, oncology, dermatology, respiratory, immunology, and essential therapies widely used in public and private healthcare systems.
The company operates in global markets, with significant presence in North America, Europe, Asia-Pacific, Latin America, and emerging regions that require accessible pharmaceutical solutions. Commercial activities serve hospitals, clinics, distributors, pharmacy retailers, and governmental entities responsible for public health programs.
Market factors influencing operations include international health regulations, competition with multinational manufacturers, patent cycles, production costs, rising demand for biosimilars, public health policies, and structural demographic trends associated with population aging that increase medication consumption.
Operational scale includes presence in more than 150 countries, thousands of registered products, manufacturing sites distributed across strategic continents, and service to millions of patients through integrated distribution networks. The workforce operates globally, comprising industrial, scientific, commercial, and administrative teams.
The operational structure encompasses active pharmaceutical ingredient facilities, formulation plants, research and development laboratories, quality control centers, and international logistics platforms. Corporate headquarters are located in the United States, with industrial and commercial subsidiaries positioned in strategic regions, in addition to regulatory support centers and specialized laboratories.
Global operations include drug development, expansion of therapeutic portfolios, optimization of supply chains, pharmacovigilance initiatives, industrial partnerships, distribution networks, and technical support services for institutional customers. Digital processes and integrated logistics systems support operational efficiency.
Shares are traded exclusively on Nasdaq under the ticker VTRS.
History and foundation
Viatris was founded in 2020 in the United States following the completion of the merger between Mylan N.V. and Upjohn, Pfizer’s division focused on globally established medicines.The early years were characterized by corporate integration, portfolio reorganization, consolidation of industrial operations, and structural adjustments to harmonize systems, supply contracts, and commercial platforms across multiple regions.
Expansion continued through strengthened international presence, growth in specialized therapies, increased participation in the biosimilars segment, and revisions to production strategies to optimize costs and address competitive pressures within the global pharmaceutical industry.
Key historical milestones include the completion of the merger in 2020, integration of Upjohn’s industrial operations, the launch of biosimilars in developed markets, and the reorganization of the operational framework to enhance global competitiveness.
Between 2020 and 2024, developments included divestments of non-core assets, enhancement of research pipelines, regulatory adjustments in key markets, reduction of corporate debt, operational efficiency initiatives, and impacts from shifts in the global healthcare environment that affected production routines and supply chains.
Additional Information
The Company Viatris Inc. (United States), is listed on Nasdaq with a market value of $ 14.87 Billions, having an equity of $ 15.22 Billions.
With a total of 45.000 employees, the company is listed in the sector of Health and categorized in industry of Pharmaceutical Products.
In the last 12 months the Company had a revenue of $ 14.12 Billions, which generated a loss in the amount of $ -3.69 Billions.
As for its main indicators, the Company has a P/E ratio of -4.03, a P/BV ratio of 0.98 and in the last 12 months the dividend yield of VTRS was at 3.76%.
The Company is traded internationally through the ticker VTRS.
